For research and educational purposes only. Not medical advice.
Piracetam Reference
Educational, not medical advice reference for Piracetam: Nootropic, Cognitive; regulatory status, evidence posture, source review, and schedule notes. Also k…
Reference summary
Decades of European clinical literature in cognitive impairment, post-stroke aphasia, and cortical myoclonus. Effect sizes are modest and methodology of older trials is debated.
- Categories
- Nootropic, Cognitive
- Aliases
- Nootropil, UCB-6215, 2-oxo-1-pyrrolidineacetamide
- Evidence posture
- human — Not FDA-approved in the US. Approved in non-US markets. Community nootropic framing extrapolates beyond the approved cognitive-impairment indication.
- Regulatory status
- No FDA-approved piracetam drug label in the US. Approved in many non-US markets (Europe, UK, Argentina) for cognitive impairment and cortical myoclonus. Sold in the US only through research-chemical channels or as an unapproved dietary ingredient — FDA has issued warning letters against piracetam-containing products.
- Content review status
- research reference